Latest Olanzapine Stories
TITUSVILLE, N.J., April 11, 2011 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) on April 6 approved INVEGAÂ® (paliperidone) extended-release tablets for the treatment of schizophrenia in adolescents 12 to 17 years of age.
A warning issued by the Food and Drug Administration regarding the use of atypical antipsychotics for the treatment of dementia was associated with a significant decline in the use of these medications for treating dementia symptoms in elderly patients.
As loved ones with dementia disappear into symptoms of aggression, agitation or delusions, families are left with few good medical solutions.
LONDON, February 2, 2011 /PRNewswire/ -- Thirteen US blockbusters will lose patent protection over the next two years, data from EvaluatePharma show, highlighting the challenges facing the pharmaceutical industry in the coming years.
Eli Lilly and Co will join forces with German drugmaker Boehringer Ingelheim to develop diabetes treatments, as the US pharmaceutical company pushes to fill a looming revenue gap created by expiring patents for several key drugs.
Top-selling drugs, known as atypical antipsychotic medications, lack evidence that theyâ€™ll actually be beneficial, according to a new study.
Researchers have found that many people currently using a specific type of antipsychotic medication are doing so for a condition that the drug has not yet been proven effective in treating.
The potential for harmful side effects associated with anti-psychotic medications for treating schizophrenia is a frustration for mental-health professionals who must balance this with the positive benefits of drugs.
INDIANAPOLIS, Sept. 10 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S.